159182-43-1 Usage
Description
4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE, also known as L755507, is a derivative of 4-acylaminobenzenesulfonamide. It is a novel compound with potential applications in various fields, particularly in the enhancement of CRISPR genome editing and as a therapeutic target for certain medical conditions.
Uses
Used in Genome Editing Applications:
4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE is used as a potent and selective β3 adrenergic receptor (β3-AR) agonist for enhancing CRISPR genome editing efficiency in pluripotent stem cells. This application aids in improving the precision and effectiveness of genome editing techniques, which can be crucial for various research and therapeutic purposes.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE may serve as a potential therapeutic target for the treatment of type II diabetes and obesity. Its role as a β3-AR agonist could help in developing new drugs or therapies that address these medical conditions more effectively.
Used in Research Applications:
4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE can also be utilized in research settings to study the role of β3-AR in various biological processes and diseases. 4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE can be a valuable tool for scientists to understand the underlying mechanisms and develop targeted therapies for specific conditions.
Biological Activity
Subnanomolar potent β 3 -adrenergic receptor partial agonist that is > 1000-fold selective over β 1 - and β 2 -adrenoceptors (EC 50 values are 0.43, 580 and > 10000 nM for activation of cloned human β 3 -, β 1 - and β 2 -adrenoceptors respectively). In vitro, stimulates lipolysis in rhesus adipocytes with an EC 50 of 3.9 nM.
Biochem/physiol Actions
L755507 is a potent β3-adrenergic receptor partial agonist with an EC50 value of 0.43 nM for β3 receptors with over 440-fold selectivity for β3 compared to β1 and β2-adrenergic receptor binding. L755507 has been shown to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs), increasing the efficiency of GFP insertion by 3-fold compared to control cells.
in vitro
l-755,507 displays an excellent activity profile as an extremely potent human β3 adrenergic receptor agonist (β3 ec50 0.43 nm), with >440-fold selectivity over β1 and β2 binding [1]. l-755,507 is also a potent and selective b3 partial agonist in rhesus monkeys as assessed by its affinity for the cloned b adrenergic receptors, and stimulates lipolysis in rhesus adipocytes with an ec50 = 3.9 nm [2].
in vivo
dose rhesus monkeys with l-755,507 elicits lipolysis and metabolic rate elevation. the ed50 for glycerolemia was 0.03 mg/kg and the ed50 for tachycardia was 2.5 mg/kg, and stimulates metabolic rate by ~ 30% after acute bolus intravenous administration of 0.1 mg/kg [2].
IC 50
13 nm (binding at the human β3 adrenergic receptor) [1]
references
[1] parmee er, ok ho, candelore mr, tota l, deng l, strader cd, wyvratt mj, fisher mh, weber ae. discovery of l-755,507: a subnanomolar human beta 3 adrenergic receptor agonist. bioorg med chem lett. 1998 may 5;8(9):1107-12.[2] fisher mh, amend am, bach tj, barker jm, brady ej, candelore mr, carroll d, cascieri ma, chiu sh, deng l, forrest mj, hegarty-friscino b, guan xm, hom gj, hutchins je, kelly lj, mathvink rj, metzger jm, miller rr, ok ho, parmee er, saperstein r, strader cd, stearns ra, macintyre de, et al. a selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. j clin invest. 1998 jun 1;101(11):2387-93.
Check Digit Verification of cas no
The CAS Registry Mumber 159182-43-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,1,8 and 2 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 159182-43:
(8*1)+(7*5)+(6*9)+(5*1)+(4*8)+(3*2)+(2*4)+(1*3)=151
151 % 10 = 1
So 159182-43-1 is a valid CAS Registry Number.
InChI:InChI=1/C30H40N4O6S/c1-2-3-4-5-19-32-30(37)33-24-10-16-29(17-11-24)41(38,39)34-25-8-6-23(7-9-25)18-20-31-21-27(36)22-40-28-14-12-26(35)13-15-28/h6-17,27,31,34-36H,2-5,18-22H2,1H3,(H2,32,33,37)/t27-/m0/s1
159182-43-1Relevant articles and documents
Discovery of L-755,507: A subnanomolar human β3 adrenergic receptor agonist
Parmee, Emma R.,Ok, Hyun O.,Candelore, Mari R.,Tota, Laurie,Deng, Liping,Strader, Catherine D.,Wyvratt, Matthew J.,Fisher, Michael H.,Weber, Ann E.
, p. 1107 - 1112 (1998)
A study of 4-acylaminobenzenesulfonamides in a cloned human β3 adrenergic receptor assay resulted in the discovery of n-hexylurea, L- 755,507 (22). This 0.43 nM β3 agonist, which is > 440-fold selective over both β1 and β2 binding, is among the most potent human β3 agonists reported to date.
